

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/679,112 10/03/2003		0/03/2003	Edward R. Kraft	ERK/001 2257		
1473	7590	10/16/2006		EXAMINER		
FISH & NEA	AVE IP	GROUP	MITRA, RITA			
ROPES & GR	AY LLP					
1251 AVENU	E OF TH	IE AMERICAS FL	ART UNIT	PAPER NUMBER		
NEW YORK		020-1105	1656			

DATE MAILED: 10/16/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)						
Office Action Summary			10/679,112	E.KRAFT					
			Examiner	Art Unit					
			Rita Mitra	1653					
Period fo	The MAILING DATE of this communic or Reply	ation app	ears on the cover sheet w	th the correspondence a	nddress				
WHIC - Exte after - If NO - Failu Any	ORTENED STATUTORY PERIOD FO CHEVER IS LONGER, FROM THE MAIN IN THE	ILING DA 137 CFR 1.13 nication. utory period w ill, by statute,	ATE OF THIS COMMUNION (1966). In no event, however, may a rivil apply and will expire SIX (6) MON cause the application to become AE	CATION. eply be timely filed ITHS from the mailing date of this BANDONED (35 U.S.C. § 133).	`				
Status									
1)⊠	Responsive to communication(s) filed	on 28 De	ecember 2005.						
	This action is FINAL . 2b)⊠ This action is non-final.								
/—	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is								
,	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Disposit	ion of Claims				•				
4) 又	4)⊠ Claim(s) <u>1-61</u> is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.								
5) Claim(s) is/are allowed.									
•	6) Claim(s) is/are rejected.								
7)	Claim(s) is/are objected to.								
	Claim(s) <u>1-61</u> are subject to restriction	and/or e	lection requirement.						
Applicat	ion Papers		·						
_		Eveniner							
	The specification is objected to by the The drawing(s) filed on is/are: a			by the Eveniner					
10)		-	•	•					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority ι	ınder 35 U.S.C. § 119								
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:									
	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
	3. Copies of the certified copies of the priority documents have been received in this National Stage								
	application from the International Bureau (PCT Rule 17.2(a)).								
* See the attached detailed Office action for a list of the certified copies not received.									
				,					
Attachmen	t(s)								
	e of References Cited (PTO-892)			ummary (PTO-413)					
	e of Draftsperson's Patent Drawing Review (PTO nation Disclosure Statement(s) (PTO/SB/08)	D-948))/Mail Date formal Patent Application					
. —	r No(s)/Mail Date		6) Other:						

Application/Control Number: 10/679,112

Art Unit: 1653

DETAILED ACTION

Applicants' Preliminary Amendment filed on December 28, 2005 is acknowledged. Amendment to the specification is noted. Claims 13 and 32 have been amended. Therefore claims 1-61 are under examination.

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-23 drawn to a composition for photokinetic delivery of a biologically active substance using pulsed incoherent light, comprising a biologically active substance, a solvent, a gelling agent and a photocatalytic agent; classified in class 530, subclass 300, class 514, subclass 2.
- II. Claims 24-53 drawn to a method of photokinetic delivery comprising preparing a solution comprising a biologically active substance and a solvent; applying said solution to a cellular surface; illuminating said solution and allowing said solution to permeate said cellular surface; classified in class 530, subclass 300, class 514, subclass 2.
- III. Claims 54-61 drawn to a device for photokinetic transdermal delivery; classified in class 530, subclass 300, class 422, subclass 50.

The inventions are distinct, each from the other because of the following reasons:

Application/Control Number: 10/679,112

Art Unit: 1653

Invention I is related to inventions II as product and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the peptide of invention I can be used on another, materially distinct process such as production of antibody. Therefore, the inventions are distinct.

Invention I and invention III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the composition of invention I is not necessary for the practice of invention III.

Invention II and invention III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the device of invention III is not necessary for the practice of invention II. Therefore the inventions are distinct.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, and because each invention requires different searches but are not co-extensive, examination of these distinct inventions would impose a serious burden on the examiner and therefor restriction for examination purposes as indicated is proper.

Species Election

For Group I, this application contains claims directed to the following patentably distinct species of the claimed invention: drug, gelling agent. The species are independent or distinct because they are structurally and functionally divergent and would require separate non-overlapping searches.

Application/Control Number: 10/679,112

Art Unit: 1653

Applicant is required under 35 U.S.C. 121 to elect a single disclosed sub-genus for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 11 is generic. Should Group I be elected, applicants are required to select single drug from claim 11 and single gelling agent from claim 17.

For Groups II and III, this application contains claims directed to the following patentably distinct species of the claimed invention: biologically active substance, drug, gelling agent. The species are independent or distinct because they are structurally and functionally divergent and would require separate non-overlapping searches.

Should Group II or III be elected, applicants are required to select single biologically active substance from claim 27, single drug from claim 31, single gelling agent from claim 35.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

Art Unit: 1653

Inquiries

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rita Mitra whose telephone number is 571-272-0954. The examiner can normally be reached on M-F, 10:00 am-7:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Rita Mitra, Ph.D.

September 19, 2006

JON WEBEH